AtriCure Inc (FRA:A5I) Stock Price, Trades & News

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	1.95
Equity-to-Asset	0.76
Debt-to-Equity	0.15
Debt-to-EBITDA	3.22
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	7.39	Distress Grey Safe
Beneish M-Score	-2.91	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	15.7
	3-Year EPS without NRI Growth Rate	52.4
	3-Year Book Growth Rate	0.2
	Future 3-5Y Total Revenue Growth Rate Estimate	12.57

Momentum Rank

5/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	78.6
	9-Day RSI	75.21
	14-Day RSI	71.96
	3-1 Month Momentum %	-1.67
	6-1 Month Momentum %	-33.33
	12-1 Month Momentum %	-61.94

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.29
	Quick Ratio	3.18
	Cash Ratio	2
	Days Inventory	211.28
	Days Sales Outstanding	43.66
	Days Payable	71.64

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2.3
	Shareholder Yield %	0.72

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	75.61
	Operating Margin %	-0.54
	Net Margin %	-0.83
	EBITDA Margin %	4.21
	FCF Margin %	8.58
	OCF Margin %	11.62
	ROE %	-0.97
	ROA %	-0.73
	ROIC %	-0.64
	3-Year ROIIC %	190.36
	ROC (Joel Greenblatt) %	1.91
	ROCE %	0.46
	Years of Profitability over Past 10-Year	1
	Moat Score	5
	Tariff Resilience Score	6

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	Forward PE Ratio	620.41
	PE Ratio without NRI	1165
	PS Ratio	3.05
	PB Ratio	3.6
	Price-to-Tangible-Book	8.37
	Price-to-Free-Cash-Flow	35.02
	Price-to-Operating-Cash-Flow	25.93
	EV-to-EBIT	667.27
	EV-to-Forward-EBIT	552.31
	EV-to-EBITDA	72.89
	EV-to-Forward-EBITDA	18.99
	EV-to-Revenue	3.07
	EV-to-Forward-Revenue	2.81
	EV-to-FCF	35.59
	Price-to-GF-Value	0.87
	Price-to-Projected-FCF	11.14
	Price-to-Median-PS-Value	0.63
	Price-to-Graham-Number	20.82
	Price-to-Net-Current-Asset-Value	10.97
	Earnings Yield (Greenblatt) %	0.15
	FCF Yield %	2.69

Financials (Next Earnings Date:2026-07-23)

Annual Quarterly TTM

FRA:A5I's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

AtriCure Inc Executives

Details

GF Value™: €34.78

FRA:A5I

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Medium warning sign with A5I. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	474.597
	EPS (TTM) (€)	-0.088
	Beta	0.0829
	3-Year Sharpe Ratio	0.01
	3-Year Sortino Ratio	0.02
	Volatility %	57.13
	14-Day RSI	71.96
	14-Day ATR (€)	0.6107
	20-Day SMA (€)	27.05
	12-1 Month Momentum %	-61.94
	52-Week Range (€)	21.8 - 62
	Shares Outstanding (Mil)	50.64

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

AtriCure Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

AtriCure Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-10-29 16:30	In 103 days
Third quarter earnings results for 2026	2026-10-29	In 102 days
Second quarter earnings conference call for 2026	2026-07-23 16:30	In 5 days
Second quarter earnings results for 2026	2026-07-23	In 4 days
Goldman Sachs 47th Annual Global Health Care Conference	2026-06-10 08:40	22.80 (+0.00%)
General meeting for 2026	2026-05-18 11:00	23.60 (+0.00%)
Guidance call for 2026	2026-05-12 10:00	21.80 (+0.00%)
First quarter earnings conference call for 2026	2026-05-05 16:30	24.20 (+0.00%)
First quarter earnings results for 2026	2026-05-05	24.20 (+0.00%)
Citizens Life Sciences Conference	2026-03-10 13:05	25.00 (+0.00%)

Show

Entries

AtriCure Inc Frequently Asked Questions

What is AtriCure Inc(FRA:A5I)'s stock price today?

The current price of FRA:A5I is €30.40. The 52 week high of FRA:A5I is €62.00 and 52 week low is €21.80.

When is next earnings date of AtriCure Inc(FRA:A5I)?

The next earnings date of AtriCure Inc(FRA:A5I) is 2026-07-23.

Does AtriCure Inc(FRA:A5I) pay dividends? If so, how much?

AtriCure Inc(FRA:A5I) does not pay dividend.

Press Release

	Subject	Date
	AtriCure to Announce Second Quarter 2026 Financial Results	2026-07-02
	AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference	2026-05-27
	AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference	2026-04-28
	AtriCure to Announce First Quarter 2026 Financial Results	2026-04-14
	AtriCure to Participate in the Citizens Life Sciences Conference	2026-02-24
	AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results	2026-02-17
	AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results	2026-01-27
	AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026	2026-01-12
	AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference	2025-12-17
	AtriCure Announces the First Patients Treated with Novel Dual Energy Platform	2025-12-11

10/Page

Articles on AtriCure Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.